Galectin Therapeutics INC 8-K filings

NASDAQ

15 May 2024

GALT

8-K: Galectin Therapeutics Provides Business Update and Reports Q1 2024 Financial Results

Galectin Therapeutics announced its Q1 2024 financial results and provided an update on its belapectin clinical trial for MASH cirrhosis, which remains on track.

NASDAQ

29 Mar 2024

GALT

Galectin Therapeutics INC

8-K: Galectin Therapeutics Announces 2023 Financial Results and Provides Business Update

Galectin Therapeutics reported its 2023 financial results, highlighted progress in its MASH cirrhosis program, and secured additional funding to extend its cash runway.